Combination of an HMG-CoA reductase inhibitor and a farnesyl-pyrophosphate synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins
US9072757B2 · kind B2 · utility
1Cited by
0References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 19, 2013 |
| Grant date | Jul 7, 2015 |
| Priority date | — |
| Expiry date | Jun 19, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61Q19/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological ageing.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.